Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer,The Prostate

当前位置： X-MOL 学术 › Prostate › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer
The Prostate ( IF 2.8 ) Pub Date : 2021-07-12 , DOI: 10.1002/pros.24194
Heidi Fettke _{1,

2,

3} , Edmond M Kwan _{1,

4} , Patricia Bukczynska ₂ , Jason A Steen ₅ , Maria Docanto ₁ , Nicole Ng _{6,

7} , Phillip Parente _{8,

9} , Andrew Mant _{8,

9} , Siavash Foroughi _{10,

11} , Carmel Pezaro ₁₂ , Christine Hauser ₂ , Tu Nguyen-Dumont _{5,

13} , Melissa C Southey _{1,

5,

13,

14} , Arun A Azad _{1,

3,

7}

Affiliation

Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Department of Medical Oncology, Monash Health, Melbourne, Australia.
Precision Medicine, School of Clinical Sciences, Monash Health, Melbourne, Australia.
Division of Personalised Oncology, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Medical Oncology Unit, Eastern Health, Melbourne, Australia.
Eastern Health Clinical School, Monash University, Melbourne, Australia.
Personalised Oncology Division, The Water and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Department of Medical Biology, The University of Melbourne, Melbourne, Australia.
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England.
Department of Clinical Pathology, University of Melbourne, Melbourne, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.

The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease and castration-resistant prostate cancer. However, its significance as a biomarker in metastatic castration-resistant prostate cancer (mCRPC), both alone and in conjunction with co-occurring AR alterations using a liquid biopsy approach has not been investigated.

中文翻译：

血浆 NCOA2 改变对转移性去势抵抗性前列腺癌的独立预后影响

雄激素受体 (AR) 通路相关基因核受体共激活因子 2 ( NCOA2 ) 在早期前列腺癌中具有确定的致癌作用，同样是转移性疾病和去势抵抗性前列腺癌的驱动因素。然而，尚未研究其作为转移性去势抵抗性前列腺癌 (mCRPC) 生物标志物的意义，无论是单独使用还是与使用液体活检方法的同时发生的AR改变相结合。

更新日期：2021-08-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>